Miguel Andújar lands on injured list due to strained right shoulder

Elsa/Getty Images
2 Comments

Update (9:42 PM ET): MLB.com’s Bryan Hoch reports that Andújar has a small labrum tear in his right shoulder. The team will treat him conservatively for two weeks, but season-ending surgery is a possibility. Not news you want to hear.

*

Ahead of Monday evening’s game against the Tigers, the Yankees announced that third baseman Miguel Andújar has been placed on the 10-day injured list due to a strained right shoulder. Infielder Tyler Wade has been recalled from Triple-A Scranton/Wilkes-Barre.

Andújar, 24, suffered the injury diving back into third base during Sunday’s loss to the Orioles. D.J. LeMahieu will likely handle the majority of time at third base in Andújar’s absence.

Losing Andújar is a big deal for the Yankees. He finished second in American League Rookie of the Year balloting last year, batting .297/.328/.527 with 27 home runs, 92 RBI, and 83 runs scored in 606 plate appearances. He was off to a slow start in 2019, mustering a meager .231 average with no extra-base hits in his first three games.

LeMahieu, 30, signed a two-year, $24 million contract with the Yankees in January. He didn’t play on Opening Day, but started at third base on Saturday and at second base on Sunday. He has registered four hits, including a double, and two walks in nine trips to the plate to start the year.

MLB, union resume blood testing after pandemic, lockout

Scott Taetsch-USA TODAY Sports
1 Comment

NEW YORK – In the first acknowledgment that MLB and the players’ association resumed blood testing for human growth hormone, the organizations said none of the 1,027 samples taken during the 2022 season tested positive.

HGH testing stopped in 2021 because of the COVID-19 pandemic. Testing also was halted during the 99-day lockout that ended in mid-March, and there were supply chain issues due to COVID-19 and additional caution in testing due to coronavirus protocols.

The annual public report is issued by Thomas M. Martin, independent program administrator of MLB’s joint drug prevention and treatment program. In an announcement accompanying Thursday’s report, MLB and the union said test processing is moving form the INRS Laboratory in Quebec, Canada, to the UCLA Laboratory in California.

MLB tests for HGH using dried blood spot testing, which was a change that was agreed to during bargaining last winter. There were far fewer samples taken in 2022 compared to 2019, when there were 2,287 samples were collected – none positive.

Beyond HGH testing, 9,011 urine samples were collected in the year ending with the 2022 World Series, up from 8,436 in the previous year but down from 9,332 in 2019. And therapeutic use exemptions for attention deficit hyperactivity disorder dropped for the ninth straight year, with just 72 exemptions in 2022.

Overall, the league issued six suspensions in 2022 for performance-enhancing substances: three for Boldenone (outfielder/first baseman Danny Santana, pitcher Richard Rodriguez and infielder Jose Rondon, all free agents, for 80 games apiece); one each for Clomiphene (Milwaukee catcher Pedro Severino for 80 games), Clostebol (San Diego shortstop Fernando Tatis Jr. for 80 games) and Stanozolol (Milwaukee pitcher J.C. Mejia for 80 games).

There was an additional positive test for the banned stimulant Clobenzorex. A first positive test for a banned stimulant results in follow-up testing with no suspension.